Genesis Therapeutics excels in AI-powered drug discovery, targeting novel proteins and untapped chemical spaces. Their advanced molecular AI platform speeds up the creation of new medicines. The team, skilled in drug hunting, deep learning, and software engineering, pushes AI in biochemistry. Their pioneering method combines 3D spatial graph modeling with cutting-edge molecular simulation to generate novel drug candidates. Genesis Therapeutics is redefining biotech, focusing on severe disorders with innovative AI integration.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/10/2023 | Series B-1 | $24.03MM | $xx.xx | $43.02B | Andreessen Horowitz, Blackrock, Fidelity, Menlo Ventures, Nventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
5,375,822
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Blackrock, Fidelity, Menlo Ventures, Nventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates
|
||||||
08/10/2023 | Series B-2 | $16MM | $xx.xx | $43.02B | Andreessen Horowitz, Blackrock, Fidelity, Menlo Ventures, Nventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
3,132,586
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Blackrock, Fidelity, Menlo Ventures, Nventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates
|
||||||
08/10/2023 | Series B | $200MM | $xx.xx | $43.02B | Andreessen Horowitz, Blackrock, Fidelity, Menlo Ventures, Nventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
39,157,330
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Blackrock, Fidelity, Menlo Ventures, Nventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates
|
||||||
12/02/2020 | Series A-1 | $5.25MM | $xx.xx | $16.13B | Andreessen Horowitz, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
1,284,849
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates
|
||||||
12/02/2020 | Series A-2 | $12MM | $xx.xx | $16.13B | Andreessen Horowitz, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
2,349,440
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates
|
||||||
12/02/2020 | Series A | $47.27MM | $xx.xx | $16.13B | Andreessen Horowitz, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
9,254,372
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Menlo Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price Associates
|
||||||
11/21/2019 | Series Seed | $4.12MM | $xx.xx | $1.03B | Andreessen Horowitz, Felicis Ventures | |
Price per Share
$xx.xx
Shares Outstanding
4,485,796
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Felicis Ventures
|